Aurinia Pharmaceuticals (NASDAQ:AUPH) Sets New 52-Week Low at $4.82

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSE:AUP)’s share price reached a new 52-week low during trading on Thursday . The stock traded as low as $4.82 and last traded at $4.87, with a volume of 115637 shares changing hands. The stock had previously closed at $4.91.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on AUPH shares. Royal Bank of Canada dropped their target price on Aurinia Pharmaceuticals from $13.00 to $8.00 and set an “outperform” rating on the stock in a research report on Friday, February 16th. Cantor Fitzgerald dropped their target price on Aurinia Pharmaceuticals from $12.00 to $10.00 and set an “overweight” rating on the stock in a research report on Friday, February 23rd. Jefferies Financial Group dropped their target price on Aurinia Pharmaceuticals from $9.50 to $9.00 and set a “hold” rating on the stock in a research report on Friday, February 16th. Finally, HC Wainwright restated a “buy” rating and set a $13.00 target price on shares of Aurinia Pharmaceuticals in a research report on Friday, March 1st. Two research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. According to MarketBeat, Aurinia Pharmaceuticals currently has an average rating of “Moderate Buy” and an average target price of $10.00.

Aurinia Pharmaceuticals Stock Up 0.8 %

The business’s fifty day moving average is $5.62 and its two-hundred day moving average is $7.30. The company has a debt-to-equity ratio of 0.20, a current ratio of 5.50 and a quick ratio of 4.99.

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last announced its quarterly earnings data on Thursday, February 15th. The biotechnology company reported ($0.19) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.03). The firm had revenue of $45.10 million during the quarter, compared to analysts’ expectations of $45.00 million. Aurinia Pharmaceuticals had a negative return on equity of 20.10% and a negative net margin of 44.45%. Aurinia Pharmaceuticals’s revenue was up 58.8% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($0.18) earnings per share. Sell-side analysts expect that Aurinia Pharmaceuticals Inc. will post -0.06 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of AUPH. China Universal Asset Management Co. Ltd. raised its position in shares of Aurinia Pharmaceuticals by 95.9% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 3,673 shares of the biotechnology company’s stock valued at $29,000 after buying an additional 1,798 shares in the last quarter. Vermillion & White Wealth Management Group LLC purchased a new stake in Aurinia Pharmaceuticals in the 4th quarter worth about $30,000. Sunbelt Securities Inc. purchased a new stake in Aurinia Pharmaceuticals in the 1st quarter worth about $31,000. Tidemark LLC purchased a new stake in Aurinia Pharmaceuticals in the 4th quarter worth about $39,000. Finally, Geneos Wealth Management Inc. increased its position in shares of Aurinia Pharmaceuticals by 54.2% during the first quarter. Geneos Wealth Management Inc. now owns 3,250 shares of the biotechnology company’s stock worth $40,000 after acquiring an additional 1,142 shares during the period. Institutional investors own 36.83% of the company’s stock.

About Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.